Physician profile
Alysa Angel
NPI 1780156281
$2,048.53
in general payments reported to CMS, 2019-2025
12 companies · $746 in 2025
The $746 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $196 · 2022: $127 · 2023: $443 · 2024: $538 · 2025: $746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,726.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $259.79 | 2025 | |
| Grifols USA, LLC | $243.70 | 2022-2024 | Prolastin-C Liquid |
| Novo Nordisk INC | $215.10 | 2024 | Wegovy |
| Sanofi-Aventis U.S. LLC | $212.64 | 2023-2024 | |
| Gilead Sciences, INC. | $202.68 | 2025 | Livdelzi |
| Astrazeneca Pharmaceuticals Lp | $201.96 | 2023-2024 | Saphnelo, Airsupra |
| Coloplast Corp | $165.67 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $123.42 | 2023 | Gvoke Hypopen |
| Acadia Pharmaceuticals INC | $119.18 | 2025 | Nuplazid |
| Horizon Therapeutics Plc | $110.48 | 2023 | Krystexxa |
| Medtronic, INC. | $105.72 | 2021 | |
| Abbvie INC. | $88.19 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alysa Angel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.